The FDA has approved a new drug called Wezlana (ustekinumab-ttwe). It is a biosimilar to Stelara, which means it is highly similar to Stelara and works the same way. Wezlana is used to treat four chronic inflammatory conditions: moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis.
For plaque psoriasis and psoriatic arthritis, Wezlana can be used in adults and children aged 6 years and older. For Crohn's disease and ulcerative colitis, it is approved only for adults. The drug is given as a shot under the skin for most conditions, but for Crohn's and ulcerative colitis, the first dose is given through an IV in a healthcare setting.
This approval gives patients and doctors another treatment option. Biosimilars like Wezlana can sometimes be more affordable, but that is not guaranteed. It is important to know that this approval does not mean Stelara is unsafe or ineffective. Both drugs are options.
If you or a loved one has one of these conditions, talk to your doctor. They can help you understand if Wezlana might be right for you. Do not stop or change your current treatment without medical advice.